Syndrome News and Research

RSS

AltheRx purchases all assets related to Solabegron from GlaxoSmithKline

AltheRx Inc., a privately-held clinical development company, announced today that it has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in Phase II clinical programs for the treatment of Overactive Bladder in women and Irritable Bowel Syndrome.

25 Mar 2011

Food safety lawyer calls on Palmyra to pay medical expenses incurred by E. coli outbreak victims

Food safety lawyer Fred Pritzker is calling on Palmyra Bologna Company, Inc., maker of Seltzer's Lebanon bologna products, to pay medical expenses and other costs incurred by victims of a multistate E. coli O157:H7 outbreak in New Jersey, North Carolina and Pennsylvania.

24 Mar 2011

Tick-borne disease identified as emerging threat

Five years ago, large numbers of farmers in central China began falling victim to an mysterious disease marked by high fever, gastrointestinal disorder and an appalling mortality rate - as high as 30 percent in initial reports. Investigators from the Chinese Center for Disease Control and Prevention hurried to the scene of the outbreak. On the basis of DNA evidence, they quickly concluded that it had been caused by human granulocytic anaplasmosis, a bacteria transmitted by tick bites.

24 Mar 2011

Toddlers who played with fewer toys show improvement in communication skills

Toddlers who played with a limited number of toys showed more improvement in their communication skills following parent-guided treatment than those receiving other community-based treatments.

23 Mar 2011

More sensitive test to detect protein troponin associated with increased diagnosis of heart attacks

In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

Asuragen introduces CE-mark approved AmplideX FMR1 PCR Kit

Asuragen, Inc. announced that they have achieved CE-marking and commercial launch in Europe of the AmplideX FMR1 PCR Kit for the detection of CGG repeats in the fragile X mental retardation gene.

23 Mar 2011

Corticosteroids may decrease occurrence of hospital-acquired pneumonia in ICU patients

Patients admitted to a hospital with major trauma and treated with the steroid hydrocortisone were less likely to be diagnosed with hospital-acquired pneumonia than patients who received placebo, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

Genetic errors in women linked to increased risk of preeclampsia

Scientists have identified genetic errors in women with autoimmune diseases that increase the risk of preeclampsia, a potentially life-threatening condition that occurs in 10 percent of all pregnancies.

23 Mar 2011

Daily dose of safflower oil can help reduce cardiovascular disease

A daily dose of safflower oil, a common cooking oil, for 16 weeks can improve such health measures as good cholesterol, blood sugar, insulin sensitivity and inflammation in obese postmenopausal women who have Type 2 diabetes, according to new research.

22 Mar 2011

Scientists develop new method for gene regulation study

Scientists at the European Molecular Biology Laboratory in Heidelberg, Germany, have developed a new method for studying gene regulation, by employing a jumping gene as an informant. Published online today in Nature Genetics, the new method is called GROMIT.

22 Mar 2011

Girls with medical conditions causing short stature go undiagnosed

Primary care doctors are less likely to refer short girls than short boys for diagnostic testing that can reveal underlying medical reasons for their short stature, according to a new study of an urban pediatric population in Philadelphia. Girls with medical conditions causing their short stature may go undiagnosed, or may be diagnosed later than boys, limiting timely treatment.

21 Mar 2011

Study identifies gene linked to higher risk of multiple sclerosis in children

Canadians have one of the highest rates of Multiple Sclerosis (MS) in the world with approximately 1,000 new cases diagnosed each year. Primarily striking in adulthood, physicians and researchers with the Canadian Pediatric Demyelinating Diseases Network (CPDDN), a multi-institutional and multidisciplinary group, have found that MS is being increasingly diagnosed in children.

21 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Prenatal alcohol exposure another risk for conduct disorder

Alcohol use during pregnancy is common and is associated with significant threats to the health and development of exposed offspring. Despite warnings from the Surgeon General to limit alcohol use if pregnant or contemplating pregnancy, a recent survey by the National Birth Defects Prevention Study(1) found that nearly one-third of women drank alcohol at some time during their pregnancy, with one-fourth of the women surveyed having drunk during the first trimester.

21 Mar 2011

Research outlines how cilia disease gene products regulate early cilium formation

An international collaboration jointly led by University College Dublin, University of Alabama and Simon Fraser University, British Columbia has outlined in the Journal of Cell Biology how cilia disease gene products regulate important aspects of early cilium formation and the integrity of the ciliary transport gate.

21 Mar 2011

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Chronic fatigue syndrome (CFS) is characterized by unexplained and debilitating tiredness and is associated with headaches, disrupted sleep, muscle pain and difficulty in concentrating. New research published by BioMed Central's open access journal BMC Medicine shows that ethnicity, depression, lack of exercise or social support, and social difficulties are major risk factors for CFS.

21 Mar 2011

Asthma an diabetes go hand in hand: Research

A new study has found that people with asthma may have a higher risk of developing diabetes and heart disease. The study looked at the relationship between asthma and four other inflammatory conditions.

21 Mar 2011

Researcher to present study on validation of salivary-biomarkers for pSS patients

Saturday, March 19, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher A.N.M. Nazmul-Hossaini will hold an oral presentation on a study titled "Validation of Salivary-Biomarkers for Sj-gren's Syndrome Detection in US Population."

19 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011

Syndrome News and Research

AltheRx purchases all assets related to Solabegron from GlaxoSmithKline

Food safety lawyer calls on Palmyra to pay medical expenses incurred by E. coli outbreak victims

Tick-borne disease identified as emerging threat

Toddlers who played with fewer toys show improvement in communication skills

More sensitive test to detect protein troponin associated with increased diagnosis of heart attacks

Asuragen introduces CE-mark approved AmplideX FMR1 PCR Kit

Corticosteroids may decrease occurrence of hospital-acquired pneumonia in ICU patients

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Genetic errors in women linked to increased risk of preeclampsia

Daily dose of safflower oil can help reduce cardiovascular disease

Scientists develop new method for gene regulation study

Girls with medical conditions causing short stature go undiagnosed

Study identifies gene linked to higher risk of multiple sclerosis in children

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Prenatal alcohol exposure another risk for conduct disorder

Research outlines how cilia disease gene products regulate early cilium formation

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Asthma an diabetes go hand in hand: Research

Researcher to present study on validation of salivary-biomarkers for pSS patients

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News